Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eisai
Pharma
EMA changes tune, endorses Leqembi with restriction
After a prior rejection, the EMA now recommends an approval to Leqembi, but only in mild Alzheimer's patients with one or no copy of the ApoE4 gene.
Angus Liu
Nov 14, 2024 12:10pm
AstraZeneca, GSK, Takeda—Fierce Pharma Asia
Nov 1, 2024 8:20am
Lilly's adjusted Kisunla regimen reduces brain swelling in trial
Oct 29, 2024 3:38pm
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
Suboptimal Leqembi vials could create millions in waste: study
Oct 14, 2024 3:00pm
Daiichi, Eisai, Granules—Fierce Pharma Asia
Sep 20, 2024 10:16am
